Inhibition of pathologic retinal neovascularization by -defensins

Authors:
  • KBKhalil Bdeir
    Khalil Bdeir
  • DCDouglas B. Cines
    Douglas B. Cines
  • FFFranz Fogt
    Franz Fogt
  • YBYasmina Bdeir
    Yasmina Bdeir
  • JLJacek Lubkowski
    Jacek Lubkowski
  • WLWuyuan Lu
    Wuyuan Lu
  • KPKlaus T. Preissner
    Klaus T. Preissner
  • HHHans-Peter Hammes
    Hans-Peter Hammes

Abstract
Proliferative retinopathies, such as those complicating prematurity and diabetes, are major causes of blindness. A prominent feature of these retinopathies is excessive neovascularization, which is orchestrated by the hypoxia-induced vascular endothelial growth factor (VEGF) stimulating endothelial cells and the integrin-mediated adhesive interactions of endothelial cells with extracellular matrix components such as fibronectin (FN). Recently, we demonstrated that α-defensins interfere with α5β1–FN interactions and dependent endothelial cell functions. Here, α-defensins were studied in hypoxia-induced proliferative retinopathy. In vitro, α-defensins specifically inhibited α5β1-integrin–dependent migration of bovine retinal endothelial cells (BRECs) to FN, attenuated the VEGF-stimulated increase in endothelial permeability, and blocked BREC proliferation and capillary sprout formation in 3-dimensional fibrin-matrices. An up-regulation of β1-integrin and FN was observed in the retinal vessels in the mouse model of hypoxia-induced retinal angiogenesis. Systemic and local administration of α-defensins reduced retinal neovascularization by 45% and 60%, respectively, and this effect was comparable to the inhibitory effect of α5β1-blocking antibody. α-Defensins were detected in human diabetic retinas associated with normal retinal vessels but were absent from proliferative lesions. Together, these data show that α-defensins inhibit pathologic retinal neovascularization in vivo and may provide a clinically efficient strategy against proliferative retinopathies.

This publication has 49 references indexed in Scilit: